Weight Management with GLP-1 Receptor Agonist, Orforglipron
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 3rd, 2025
|
Overweight and obesity substantially raise the risk of numerous chronic diseases. GLP-1 receptor agonists have been shown to improve glycemic control, support weight loss, and lower cardiovascular risk. Orforglipron, a GLP-1 agonist already used for type 2 diabetes, was evaluated in a study funded by Eli Lilly to explore its effectiveness for weight management.
The phase 3 trial enrolled 3127 participants with an average body mass index of 37 and a mean body weight of 103 kg. Baseline laboratory results showed mean LDL cholesterol levels of 119 mg/dL and triglyceride levels of 139 mg/dL. Participants were randomly assigned to receive either placebo or daily orforglipron at doses of 6 mg, 12 mg, or 36 mg.
After 72 weeks, orforglipron led to meaningful weight reduction: body weight decreased by 7.5%, 8.4%, and 11.2% across the three dose levels, compared with only 2.1% in the placebo group. All orforglipron doses were also associated with significant improvements in LDL cholesterol and triglyceride levels. Gastrointestinal side effects were more common among those receiving orforglipron. The overall safety profile is encouraging, particularly given concerns that small-molecule therapies may bind unintended targets.
The phase 3 trial enrolled 3127 participants with an average body mass index of 37 and a mean body weight of 103 kg. Baseline laboratory results showed mean LDL cholesterol levels of 119 mg/dL and triglyceride levels of 139 mg/dL. Participants were randomly assigned to receive either placebo or daily orforglipron at doses of 6 mg, 12 mg, or 36 mg.
After 72 weeks, orforglipron led to meaningful weight reduction: body weight decreased by 7.5%, 8.4%, and 11.2% across the three dose levels, compared with only 2.1% in the placebo group. All orforglipron doses were also associated with significant improvements in LDL cholesterol and triglyceride levels. Gastrointestinal side effects were more common among those receiving orforglipron. The overall safety profile is encouraging, particularly given concerns that small-molecule therapies may bind unintended targets.